Inogen (INGN) Q4 2025 earnings review
Profitability Reached in FY25, But Growth Slows Entering 2026
Inogen delivered a mixed Q4 to close out a turnaround year. While the company achieved positive full-year Adjusted EBITDA for the first time since 2021, Q4 revenue growth decelerated to just 2.0% YoY, and Adjusted EBITDA dipped back into negative territory (-$1.7M). A shift toward lower-margin international B2B sales continued to pressure gross margins, while the U.S. rentals business remains a persistent headwind. Despite near-term softness—reflected in a flat Q1 2026 revenue guide—management expects full-year growth to accelerate to ~6% driven by new product launches (Voxi 5, Simeox). Armed with a debt-free balance sheet and $120.9M in cash, the board authorized a new $30M share repurchase program.
🐂 Bull Case
Stringent material cost reductions and operational efficiencies slashed the FY25 net loss by 36% and generated $2.7M in positive Adjusted EBITDA, marking a successful operational turnaround.
The introduction of the Voxi 5 stationary oxygen concentrator dramatically expands Inogen's addressable market, as ~90% of long-term oxygen therapy patients rely on stationary devices.
🐻 Bear Case
Total gross margin fell 220 basis points YoY in Q4 to 43.1%. The strategic shift toward international business-to-business (B2B) channels is driving volume but eroding profitability profiles compared to direct-to-consumer sales.
The high-margin U.S. rental segment continues to shrink, falling 4.5% YoY in Q4, pressured by lower private payer reimbursement rates and a declining base of patients on service.
⚖️ Verdict: ⚪
Neutral. Management has successfully stopped the bleeding on the bottom line and stabilized the balance sheet, but top-line momentum has stalled. Reinvigorating U.S. sales and defending gross margins will be critical to achieving the promised FY26 acceleration.
Key Themes
Channel Mix Squeezing Gross Margins
The success of Inogen's international sales growth is a double-edged sword. Total gross margin declined from 45.3% in 24Q4 to 43.1% in 25Q4. Management explicitly attributed this to channel mix. While international B2B is a reliable volume engine, its lower pricing power structurally caps gross margin expansion unless offset by significant material cost reductions.
International Sales Leading Growth
International sales remain the standout performer, growing 14.8% YoY in Q4 to $32.5M. For the full year, the segment grew 18.4%. By deepening relationships with DME partners globally and capturing market share as patients convert from traditional tanks to portable oxygen concentrators (POCs), Inogen has found a reliable growth pillar outside the U.S.
Persistent U.S. Market Headwinds
Both U.S. sales (-5.1% YoY) and U.S. rentals (-4.5% YoY) declined in Q4. Management pointed to a reduced number of rental patients on service and reimbursement mix issues. The upcoming flat Q1 2026 guidance is heavily pinned on continued U.S. rental weakness, suggesting this segment has not yet found its floor.
Voxi 5 Expanding Total Addressable Market
The launch of the Voxi 5 stationary oxygen concentrator represents a major strategic shift. Historically focused on portable units (used by only ~23% of patients), Inogen can now target the ~90% of long-term oxygen therapy patients requiring stationary solutions, enabling bundled sales to B2B partners.
Cost Discipline Restoring Operating Leverage
Despite margin pressures, strict operational control drove a 29.0% improvement in full-year operating losses. Q4 operating expenses fell 6.6% YoY to $44.5M. This discipline allowed the company to generate positive full-year Adjusted EBITDA ($2.7M) and fund a new $30M buyback program without taking on debt.
Digital Health & Patient Engagement
The launch of the Inogen patient portal illustrates a push toward a digital health ecosystem. The self-service platform manages insurance requirements and accessory ordering, aiming to reduce administrative overhead and increase patient stickiness in the challenging direct-to-consumer channel.
Secular Shift: Tanks to POCs
The macro transition from traditional oxygen tanks to Portable Oxygen Concentrators (POCs) continues to act as a rising tide. This secular tailwind was a primary driver behind the robust 20.6% YoY unit volume growth in Q4, even as pricing and channel mix muted the overall revenue impact.
Other KPIs
Accelerating. Up 20.6% YoY compared to 38,400 units in 24Q4. This starkly contrasts with the 2.0% total revenue growth, underscoring that volume demand is robust, but unit economics are deteriorating due to the shift from retail to wholesale (B2B) pricing.
Down 6.5% YoY from $197.3M in FY24. The reduction was driven by material cost reductions and operational efficiencies. Sales & Marketing expenses fell by $5.4M, and G&A fell by $5.2M, which was crucial to achieving positive Adjusted EBITDA for the year.
Stable. Slightly down from $124.5M at the end of Q3 but still represents a fortress balance sheet with zero debt. This liquidity comfortably funds the newly announced $30M share repurchase program while leaving room for the Simeox commercialization rollout.
Guidance
Decelerating. After posting 5.5% YoY growth in 25Q1, management expects flat growth for 26Q1. This is attributed to channel mix and lower expected U.S. rentals revenue driven by reimbursement headwinds and reduced patients on service.
Accelerating. The midpoint of $369.5M implies ~6.0% YoY growth, an acceleration from the 3.9% growth achieved in FY25. Since Q1 is guided flat, this implies a significantly back-half-weighted growth curve for 2026, heavily reliant on the ramp-up of new products like Voxi 5.
Key Questions
Margin Floor for B2B
With gross margins compressing to 43.1% due to the international B2B channel mix, where does management see the structural floor for gross margins, and can manufacturing efficiencies offset this headwind in 2026?
U.S. Rentals Stabilization
The U.S. rentals business continues to shrink and is explicitly cited as a drag on Q1 2026 guidance. What leading indicators point to a bottoming out of the patient-on-service declines?
Voxi 5 Cannibalization vs. Expansion
As the Voxi 5 stationary concentrator rolls out, what percentage of its sales are expected to be bundled with existing POC lines, and is there any risk of it cannibalizing higher-margin portable unit sales?
China Expansion Timeline
Following the strategic collaboration with Yuwell Medical, what is the regulatory and commercial timeline for introducing Inogen products into the Chinese market in 2026?